疫苗开发的未来
疫苗是历史上最成功的公共卫生干预措施之一,已消灭天花、接近消灭脊髓灰质炎并大幅降低多种疾病的病例数和全球发病率。然而,疫苗开发对复杂传染病及非传染性疾病(包括癌症、自身免疫、过敏、神经退行性和代谢性疾病)仍不成功,且开发过程昂贵、缓慢、费力,耗时数十年、耗资数十亿美元,成功率不足10%。亟需改进疫苗本身的有效性及开发流程。
要点
- 疫苗已消灭天花、接近消灭脊髓脊灰并降低多种疾病负担。
- 复杂传染病及非传染性疾病(癌症、自身免疫等)疫苗开发仍不成功。
- 当前疫苗开发成本高、周期长(数十年)、成功率不足10%。
核心结论
- 亟需改进疫苗有效性及疫苗开发流程。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 疫苗已消灭天花、接近消灭脊髓灰质炎并大幅降低多种疾病的病例数和全球发病率。
- 疫苗开发对复杂传染病及非传染性疾病(包括癌症、自身免疫、过敏、神经退行性和代谢性疾病)不成功。
- 当前疫苗开发昂贵、缓慢、费力,耗时数十年、耗资数十亿美元,成功率不足10%。
- 部分疫苗如天花疫苗单次免疫即可终身保护,其他疫苗效果较差,常需多次免疫,对婴儿、老年人及发展中国家人群效果更差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are one of the most successful public health interventions in our history resulting in eradication of small pox, near eradication of polio and major reductions in case number and global morbidity and mortality for numerous diseases (Centers for Disease C, 1999) [1]. However, vaccine development has been less successful against complex infectious diseases, where pathogen variability and/or immune evasion mechanisms have combined to pose major obstacles, and have been unsuccessful against non-communicable diseases, including cancer, autoimmunity, allergy, neurodegenerative and metabolic diseases (Koff et al., 2013) [2]. In addition, the current state of vaccine development is an expensive, slow and laborious process, costing billions of dollars, taking decades, with less than a 10% rate of success (Pronker et al., 2013) [3]. While some vaccines, such as the smallpox vaccine approach the gold standard of life-long protection in everyone following a single immunization, other vaccines are less effective, often requiring multiple immunizations, being less effective to populations most susceptible to disease such as infants, the elderly, and those living in the developing world. There is clearly an urgent need to determine ways to improve not just the effectiveness of the vaccines themselves but also the very processes by which they are developed.
引用
- Koff WC, Schenkelberg T. The future of vaccine development. Vaccine. 2019. PMID: 31443989. doi:10.1016/j.vaccine.2019.07.101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。